Cardiometabolic Risk

Cardiometabolic Risk

Cardiometabolic risk covers a cluster of linked metabolic problems that together raise the chance of heart attack, stroke and type 2 diabetes. The main risk factors are abdominal obesity, high triglycerides, low HDL cholesterol, high blood pressure, high fasting glucose and insulin resistance. They often occur together and share root causes, especially low-grade inflammation driven by visceral fat and damage to the lining of blood vessels.

No single marker captures this risk. People with several risk factors at once face a multiplied, not just added, chance of harm. That insight has pushed drug development toward treatments that tackle the root cause of cardiometabolic disease, mainly excess body fat, rather than treating each risk factor separately. Losing >10% of body weight has been shown to improve nearly every cardiometabolic measure, including blood pressure, lipids, blood sugar control and inflammatory markers.

In Phase 2 trials, retatrutide’s large weight loss brought broad cardiometabolic improvements. In Phase 3, TRIUMPH-2 (1,152 adults with obesity and type 2 diabetes, 80 weeks) and TRIUMPH-3 (1,949 adults with a BMI of 35 or more and cardiovascular disease) reported topline results on July 23, 2026: -20.8% and -22.6% weight loss at 12 mg, respectively. These trial designs reflect a growing view that obesity treatment should be judged not only by how much weight comes off but also by what that does for heart and metabolic health.